Email this article Sensitivity of influenza viruses to specific drugs in Russia during 2017−2020. The rare finds and perspective antivirals
- Authors: Breslav N.V.1, Krasnoslobotsev K.G.1, Mukasheva E.A.1, Kirillova E.S.1, Rosatkevich A.G.1, Kolobukhina L.V.1, Burtseva E.I.1
-
Affiliations:
- N.F.Gamaleya Federal Research Centre of Epidemiology and Microbiology
- Issue: Vol 25, No 2 (2020)
- Pages: 65-77
- Section: ORIGINAL STUDIES
- URL: https://journals.rcsi.science/1560-9529/article/view/46440
- DOI: https://doi.org/10.17816/EID46440
- ID: 46440
Cite item
Full Text
Abstract
BACKGROUND: The article presents the results of studying the effectiveness of anti-influenza drugs in Russia in the period 2017−2020. The sensitivity of circulating strains of influenza viruses A(H1N1)pdm09, A(H3N2) and B to neuraminidase inhibitors – oseltamivir, zanamivir and rimantadine was determined. The analysis of scientific articles by both domestic and foreign researchers on new promising chemotherapy drugs for influenza viruses was carried out.
AIMS: study of the sensitivity of influenza viruses circulating strains to specific anti-influenza drugs in the framework of monitoring in the period 2017–2020.
MATERIALS AND METHODS: The study was conducted within the framework of epidemiological surveillance of the influenza viruses circulation using the collection of the influenza etiology and epidemiology laboratory with the following criteria for selecting strains isolated from pregnant women, patients with complicated flu infection and severe acute respiratory infection (SARI), lethal outcomes, as well as patients undergoing treatment with specific drugs. Virological, immunological, and molecular genetic methods were used in the study, and following drugs substances were used: oseltamivir carboxylate, zanamivir, and rimantadine.
RESULTS: For the period 2017−2020, the sensitivity of 541 influenza A and B viruses epidemic strains to anti-influenza drugs was studied. Most of the studied strains remained sensitive to neuraminidase inhibitors. The exceptions were: in 2017/2018 — 5 strains of the influenza A(H1N1)pdm09 virus resistant to oseltamivir and 2 strains of the influenza B virus, one with reduced sensitivity to oseltamivir, the second — to zanamivir; in 2019/2020 — influenza A(H1N1)pdm09 virus strain with reduced sensitivity to both drugs.
In the 2018/2019 season, an influenza A/Moscow/246/2018 A(H1N1)pdm09 strain was found to be sensitive to rimantadine.
CONCLUSIONS: The main and most common genetic markers of influenza viruses resistance to specific drugs are: for oseltamivir — substitution H274Y in the influenza A(H1N1)pdm09 virus NA; for rimantadine — substitution S31N in the influenza A(H1N1)pdm09 and A(H3N2) viruses M2 protein. Taking into account the low frequency of strains with reduced sensitivity to drugs with antineuraminidase activity, can confidently approve that they remain the drugs of choice for the treatment and prevention of influenza infection.
Full Text
##article.viewOnOriginalSite##About the authors
Natalia V. Breslav
N.F.Gamaleya Federal Research Centre of Epidemiology and Microbiology
Author for correspondence.
Email: n.belyakova1983@gmail.com
ORCID iD: 0000-0002-6946-5119
Ph.D., Senior Researcher Influenza Etiology and Epidemiology Lab.
Russian Federation, Russia 123098, Moscow, Gamaleya str. 18Kirill G. Krasnoslobotsev
N.F.Gamaleya Federal Research Centre of Epidemiology and Microbiology
Email: kkg_87@mail.ru
ORCID iD: 0000-0003-1745-9128
researcher of the influenza etiology and epidemiology laboratory
Russian Federation, Russia 123098, Moscow, Gamaleya str. 18Evgeniya A. Mukasheva
N.F.Gamaleya Federal Research Centre of Epidemiology and Microbiology
Email: mukasheva_evgeniya@mail.ru
ORCID iD: 0000-0002-5688-5309
researcher of the influenza etiology and epidemiology laboratory
Russian Federation, Russia 123098, Moscow, Gamaleya str. 18Elena S. Kirillova
N.F.Gamaleya Federal Research Centre of Epidemiology and Microbiology
Email: esshevchenko@yandex.ru
ORCID iD: 0000-0001-7977-7530
Ph.D., leading researcher of the influenza etiology and epidemiology laboratory
Russian Federation, Russia 123098, Moscow, Gamaleya str. 18Alexandra G. Rosatkevich
N.F.Gamaleya Federal Research Centre of Epidemiology and Microbiology
Email: rosatkevich@me.com
ORCID iD: 0000-0003-0008-8711
junior researcher of the influenza etiology and epidemiology laboratory
Russian Federation, Russia 123098, Moscow, Gamaleya str. 18Lyudmila V. Kolobukhina
N.F.Gamaleya Federal Research Centre of Epidemiology and Microbiology
Email: lkolobukhina@mail.ru
ORCID iD: 0000-0001-5775-3343
ScD, professor, head of department of viral hepatitis and clinical virology
Russian Federation, Russia 123098, Moscow, Gamaleya str. 18Elena I. Burtseva
N.F.Gamaleya Federal Research Centre of Epidemiology and Microbiology
Email: elena-burtseva@yandex.ru
ORCID iD: 0000-0003-2518-6801
ScD, Lead researcher of influenza etiology and epidemiology laboratory
Russian Federation, Russia 123098, Moscow, Gamaleya str. 18References
- Leneva IA, Russell RJ, Boriskin YS, Hay AJ. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009;81(2):132-140. doi: 10.1016/j.antiviral.2008.10.009.
- Burtseva EI, Breslav NV, Kirillova ES, et al. Influenza virus neuraminidase inhibitors: efficacy during post-pandemics period. Effective pharmacotherapy. Epidemiology and infections. 2016;44(2):32-36. (In Russ).
- Beigel JH, Nam HH, Adams PL, et al. Advances in respiratory virus therapeutics − A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019;167:45-67. doi: 10.1016/j.antiviral.2019.04.006.
- Lackenby A, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017. Antiviral Res. 2018;157:38-46. doi: 10.1016/j.antiviral.2018.07.001.
- Colman PM, Varghese JN, Laver WC. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature. 1983;303(5912):41-44. doi: 10.1038/303041a0.
- L’vov DK, Burtseva EI, Prilipov AG, et al. The 24 May, 2009 isolation of the first A/IIV-Moscow/01/2009 (H1N1)swl strain similar to swine A(H1N1) influenza virus from the first Moscow case detected on May 21, 2009, and its deposit in the State Collection of Viruses (SCV No. 2452 dated May 24, 2009). Problems of Virology. 2009;54(5):10-14. (In Russ).
- Sominina A, Burtseva E, Eropkin M, et al. Influenza surveillance in Russia based on epidemiological and laboratory data for the period from 2005 to 2012. Am J Infect Dis. 2013;9(3):77-93. doi: 10.3844/ajidsp.2013.77.93.
- WHO Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. World Health Organization; 2011. 153 р.
- Мatrosovich M, Matrosovich T, Carr G, et al. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol. 2003;77(15):8418-8425. doi: 10.1128/jvi.77.15.8418-8425.2003.
- Metodicheskie rekomendatsii “Vydelenie virusov sezonnogo i potentsial’no pandemicheskogo grippa v kletochnykh kul’turakh i kurinykh embrionakh i ikh identifikatsiya” (utverzhdeny FS po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka 18 aprelya 2006 g. № 0100/4430-06-34). (In Russ). Available from: https://www.garant.ru/products/ipo/prime/doc/4082733/.
- Leang SK, Hurt AC. Fluorescence-based neuraminidase inhibition assay to assess the susceptibility of influenza viruses to the neuraminidase inhibitor class of antivirals. J Vis Exp. 2017;122:55570. doi: 10.3791/55570.
- Zhou B, Donnelly ME, Scholes DT, et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J Virol. 2009;83(19):10309-10313. doi: 10.1128/jvi.01109-09.
- Zhou B, Lin X, Wang W, et al. Universal influenza b virus genomic amplification facilitates sequencing, diagnostics, and reverse genetics. J Clin Microbiol. 2014;52(5):1330-1337. doi: 10.1128/JCM.03265-13.
- L’vov DK, Yashkulov KB, Prilipov AG, et al. Detection of amino acid substitutions of asparaginic acid for glycine and asparagine at the receptor-binding site of hemagglutinin in the variants of pandemic influenza A/H1N1 virus from patients with fatal outcome and moderate form of the disease. Problems of Virology. 2010;55(3):15-18. (In Russ).
- Burtseva YeI, Shevchenko YeS, Leneva IA, et al. Rimantadine and arbidol sensitivity of influenza viruses that caused epidemic morbidity rise in Russia in the 2004−2005 season. Problems of Virology. 2007;52(2):24-29. (In Russ).
- Breslav NV, Shevchenko ES, Abramov DD, et al. Efficacy of anti-neuraminidase drugs application during and after an influenza pandemic. Problems of Virology. 2013;58(1):28-32. (In Russ).
- Takashita E, Meijer A, Lackenby A, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013−2014. Antiviral Res. 2015;117:27-38. doi: 10.1016/j.antiviral.2015.02.003.
- Breslav N, Krasnoslobodtsev K, Mukasheva E, et al. The facts of influenza antivirals susceptibility surveillance in Russia. Clinical sciences: therapeutics – antivirals: options X for the Control of Influenza; 28 Aug − 1 Sep 2019, Suntec Singapure, Abstract Book; 2019. 234 р.
- WHO. Weekly epidemiological record Releve epidemiologique hebdomadaire. Review of the 2014−2015 influenza season in the northern hemisphere. Available from: http://www.who.int/wer/2015/wer9023.pdf.
- WHO. Flu News Europe. Weekly influenza overview. Available from: http://flunewseurope.org.
- WHO. Seasonal influenza in the WHO European Region, 2017−2018 early season (2018). Available from: http://www.euro.who.int/en/health-topics/communicable-diseases/influenza/publications/2018/seasonal-influenza-in-the-who-european-region,-2017-2018-early-season.
- WHO. Influenza: Surveillance and monitoring (GISRS). Available from: https://www.who.int/influenza/surveillance_monitoring/en/.
- WHO. Influenza: FluNet summary. Available from: http://www.who.int/influenza/gisrs_laboratory/updates/summaryreport/en.
- CDC. Weekly U.S. Influenza Surveillance Report. Available from: https://www.cdc.gov/flu/weekly/.
- Noshi T, Kitano M, Taniguchi K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018;160:109-117. doi: 10.1016/j.antiviral.2018.10.008.
Supplementary files
